Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: UCB Pharma S.A., Allée de la Recherche 60, B-1070, Bruxelles, Belgium
Vimpat 10 mg/ml solution for infusion.
| Pharmaceutical Form |
|---|
|
Solution for infusion. Clear, colourless solution. |
Each ml of solution for infusion contains 10 mg lacosamide. Each vial of 20 ml solution for infusion contains 200 mg lacosamide.
Excipients with known effect: Each ml of solution for infusion contains 2.99 mg sodium.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Lacosamide |
Lacosamide is a functionalised amino acid. The precise mechanism by which lacosamide exerts its antiepileptic effect in humans remains to be fully elucidated. |
| List of Excipients |
|---|
|
Water for injections |
Colourless type I glass vial with a chlorobutyl rubber closure coated with a fluoropolymer. Packs of 1x20 ml and 5x20 ml.
Not all pack sizes may be marketed.
UCB Pharma S.A., Allée de la Recherche 60, B-1070, Bruxelles, Belgium
EU/1/08/470/016-017
Date of first authorisation: 29 August 2008
Date of latest renewal: 31 July 2013
| Drug | Countries | |
|---|---|---|
| VIMPAT | Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
